Latest Breaking News On - Their processes - Page 2 : comparemela.com

Health your username 2 hours ago On Wednesday in the District of Delaware, Shilpa Pharma Inc. filed a complaint against Novartis Pharmaceuticals Corporation, alleging that the defendant’s drug Gilenya infringes on one of the plaintiff’s patents. Shilpa is the assignee of United States Patent No. 9,266,816 (the ’816 patent), “Fingolimod Polymorphs and Their Processes,” according to the complaint. Novartis holds New Drug Application (NDA) No. 022527 for Gilenya capsules in 0.5 and 0.25 mg strengths, which is listed in the Food and Drug Administration (FDA)’s drug patent database, Orange Book. The active ingredient in Gilenya is fingolimod hydrochloride, which is used to treat multiple sclerosis in patients 10 years and older.

United statesFingolimod polymorphsShilpa pharma incKatzenstein jenkinsNovartis pharmaceuticals corporationDrug administrationShilpa pharmaUnited states patentTheir processesNew drug applicationஒன்றுபட்டது மாநிலங்களில்ஷில்பா பார்மா இன்க்கதஜென்சிதேன் ஜென்கின்ஸ்நோவர்த்திச் மருந்துகள் நிறுவனம்ஷில்பா பார்மாஒன்றுபட்டது மாநிலங்களில் காப்புரிமை